Elanco Animal Health Incorporated Research and Development Expense
Elanco Animal Health Incorporated (ELAN) reported Research and Development Expense of $92.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Elanco Animal Health Incorporated research and development expense for the quarter ending 2026-06-30 was $92.00M, a 0.00% change year-over-year.
- Elanco Animal Health Incorporated research and development expense for the quarter ending 2026-03-31 was $97.00M, a 3.19% increase year-over-year.
- Elanco Animal Health Incorporated research and development expense for the quarter ending 2025-12-31 was $93.00M, a 14.81% increase year-over-year.
- Elanco Animal Health Incorporated research and development expense for the quarter ending 2025-09-30 was $89.00M, a 2.30% increase year-over-year.
- Elanco Animal Health Incorporated research and development expense for fiscal 2025 was $368.00M, a 6.98% increase from fiscal 2024.
- Elanco Animal Health Incorporated research and development expense for fiscal 2024 was $344.00M, a 5.20% increase from fiscal 2023.
- Elanco Animal Health Incorporated research and development expense for fiscal 2023 was $327.00M, a 1.87% increase from fiscal 2022.
- Elanco Animal Health Incorporated research and development expense for fiscal 2022 was $321.00M, a 13.01% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.00M 10-Q · filed 2026-08-05 | $189.00M 10-Q · filed 2026-08-05 | $282.00M derived: sum of 3 quarters · filed 2026-08-05 | $371.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $97.00M 10-Q · filed 2026-05-06 | $190.00M derived: sum of 2 quarters · filed 2026-05-06 | $279.00M derived: sum of 3 quarters · filed 2026-05-06 | $371.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $93.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $182.00M derived: sum of 2 quarters · filed 2026-02-24 | $274.00M derived: sum of 3 quarters · filed 2026-08-05 | $368.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $89.00M 10-Q · filed 2025-11-05 | $181.00M derived: sum of 2 quarters · filed 2026-08-05 | $275.00M 10-Q · filed 2025-11-05 | $356.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $92.00M 10-Q · filed 2026-08-05 | $186.00M 10-Q · filed 2026-08-05 | $267.00M derived: sum of 3 quarters · filed 2026-08-05 | $354.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $94.00M 10-Q · filed 2026-05-06 | $175.00M derived: sum of 2 quarters · filed 2026-05-06 | $262.00M derived: sum of 3 quarters · filed 2026-05-06 | $351.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $168.00M derived: sum of 2 quarters · filed 2026-02-24 | $257.00M derived: sum of 3 quarters · filed 2026-02-24 | $344.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $87.00M 10-Q · filed 2025-11-05 | $176.00M derived: sum of 2 quarters · filed 2025-11-05 | $263.00M 10-Q · filed 2025-11-05 | $342.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $89.00M 10-Q · filed 2025-08-07 | $176.00M 10-Q · filed 2025-08-07 | $255.00M derived: sum of 3 quarters · filed 2026-02-24 | $341.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $87.00M 10-Q · filed 2025-05-07 | $166.00M derived: sum of 2 quarters · filed 2026-02-24 | $252.00M derived: sum of 3 quarters · filed 2026-02-24 | $333.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $165.00M derived: sum of 2 quarters · filed 2026-02-24 | $246.00M derived: sum of 3 quarters · filed 2026-02-24 | $327.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $86.00M 10-Q · filed 2024-11-07 | $167.00M derived: sum of 2 quarters · filed 2024-11-07 | $248.00M 10-Q · filed 2024-11-07 | $328.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $81.00M 10-Q · filed 2024-08-08 | $162.00M 10-Q · filed 2024-08-08 | $242.00M derived: sum of 3 quarters · filed 2025-02-25 | $320.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $81.00M 10-Q · filed 2024-05-08 | $161.00M derived: sum of 2 quarters · filed 2025-02-25 | $239.00M derived: sum of 3 quarters · filed 2025-02-25 | $321.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $158.00M derived: sum of 2 quarters · filed 2025-02-25 | $240.00M derived: sum of 3 quarters · filed 2025-02-25 | $321.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $78.00M 10-Q · filed 2023-11-07 | $160.00M derived: sum of 2 quarters · filed 2023-11-07 | $241.00M 10-Q · filed 2023-11-07 | $333.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $82.00M 10-Q · filed 2023-08-07 | $163.00M 10-Q · filed 2023-08-07 | $255.00M derived: sum of 3 quarters · filed 2024-02-26 | $349.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $81.00M 10-Q · filed 2023-05-09 | $173.00M derived: sum of 2 quarters · filed 2024-02-26 | $267.00M derived: sum of 3 quarters · filed 2024-02-26 | $361.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $92.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $186.00M derived: sum of 2 quarters · filed 2024-02-26 | $280.00M derived: sum of 3 quarters · filed 2024-02-26 | $369.00M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $94.00M 10-Q · filed 2022-11-08 | $188.00M derived: sum of 2 quarters · filed 2022-11-08 | $277.00M 10-Q · filed 2022-11-08 | $392.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $94.00M 10-Q · filed 2022-08-08 | $183.00M 10-Q · filed 2022-08-08 | $298.00M derived: sum of 3 quarters · filed 2023-03-01 | $386.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $89.00M 10-Q · filed 2022-05-09 | $204.00M derived: sum of 2 quarters · filed 2023-03-01 | $292.00M derived: sum of 3 quarters · filed 2023-03-01 | $351.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $115.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $203.00M derived: sum of 2 quarters · filed 2023-03-01 | $262.00M derived: sum of 3 quarters · filed 2023-03-01 | $329.00M 10-K · filed 2023-03-01 | $327.00M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $88.00M 10-Q · filed 2021-11-05 | $88.10M 10-Q · filed 2020-11-06 | $147.00M derived: sum of 2 quarters · filed 2021-11-05 | $214.00M 10-Q · filed 2021-11-05 | $214.30M 10-Q · filed 2020-11-06 | $281.20M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $59.00M 10-Q · filed 2021-08-09 | $59.40M 10-Q · filed 2020-07-30 | $126.00M 10-Q · filed 2021-08-09 | $126.20M 10-Q · filed 2020-07-30 | $193.20M derived: sum of 3 quarters · filed 2022-02-28 | $263.10M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $67.00M 10-Q · filed 2021-05-07 | $66.80M 10-Q · filed 2020-05-07 | $134.20M derived: sum of 2 quarters · filed 2022-02-28 | $204.10M derived: sum of 3 quarters · filed 2022-02-28 | $272.90M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $67.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $137.10M derived: sum of 2 quarters · filed 2022-02-28 | $205.90M derived: sum of 3 quarters · filed 2022-02-28 | $270.00M 10-K · filed 2022-02-28 | $270.10M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $69.90M 10-Q · filed 2020-11-06 | $138.70M derived: sum of 2 quarters · filed 2020-11-06 | $202.80M 10-Q · filed 2020-11-06 | $263.90M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $68.80M 10-Q · filed 2020-07-30 | $132.90M 10-Q · filed 2020-07-30 | $194.00M derived: sum of 3 quarters · filed 2021-03-01 | $252.90M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $64.10M 10-Q · filed 2020-05-07 | $125.20M derived: sum of 2 quarters · filed 2021-03-01 | $184.10M derived: sum of 3 quarters · filed 2021-03-01 | $245.50M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $61.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $120.00M derived: sum of 2 quarters · filed 2021-03-01 | $181.40M derived: sum of 3 quarters · filed 2021-03-01 | $246.60M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $58.90M 10-Q · filed 2019-11-08 | $120.30M derived: sum of 2 quarters · filed 2019-11-08 | $185.50M 10-Q · filed 2019-11-08 | $247.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $61.40M 10-Q · filed 2019-08-13 | $126.60M 10-Q · filed 2019-08-13 | $188.60M derived: sum of 3 quarters · filed 2020-02-28 | $250.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $65.20M 10-Q · filed 2019-05-14 | $127.20M derived: sum of 2 quarters · filed 2020-02-28 | $189.10M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $123.90M derived: sum of 2 quarters · filed 2020-02-28 | $251.70M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | $61.90M 10-Q · filed 2018-11-08 | $189.70M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | $265.80M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |